SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Fermi, Inc. engages in the development of energy infrastructure. It intends to develop an energy and data center development campus to support the needs of to-be-built AI infrastructure. The company was founded by Rick Perry, Toby Neugebauer and Griffin Perry on January 10, 2025 and is headquartered in Amrillo, TX.

Fermi Inc

Fermi LLC

Fermi LLC is trending as investors weigh potential M&A activity and boardroom disputes against the companys underlying power infrastructure value. The community is focused on the possibility of imminent tenant signings or a strategic buyout, with active debate centered on whether recent price action is a fundamental re-rating or a volatile reaction to governance battles and speculative rumors.

Space Exploration Technologies Corp., doing business as SpaceX, operates as an aerospace manufacturer, launch service provider, and satellite communications company. It is building the integrated hardware and software infrastructure of the future across space, connectivity, and AI. The firm designs, manufactures, launches, and operates products and services built on cutting-edge technologies, including rockets and spacecraft. The company was founded by Elon Reeve Musk in 2002 and is headquartered in Starbase, TX.

Space Exploration Technologies Corp. - Ordinary Shares - Class A

SpaceX

SpaceX is currently trending as investors debate its explosive IPO valuation and speculative mechanics, with the market intensely focused on a limited public float and forced buying from index inclusion. While bulls are energized by orbital achievements and AI integration, many community members express concerns over extreme price multiples and volatility, positioning the symbol as a high-stakes battleground between speculative hype and traditional fundamental valuation.

Ocular Therapeutix, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies for diseases and conditions of the eye. Its product pipeline includes Dextenza, OTX-TP, and OTX-TIC. The company was founded by Amarpreet S. Sawhney and Farhad Khosravi on September 12, 2006 and is headquartered in Bedford, MA.

Ocular Therapeutix Inc

Ocular Therapeutix is trending as investors focus on the company's confirmed single-trial pathway for AXPAXLI, with community discourse centered on the Q4 2026 NDA submission timeline and potential for future acquisition by major pharmaceutical players. While some investors express optimism regarding the regulatory de-risking event, others remain cautious, debating the long-term competitive impact of the data and the significance of recent trading volatility.

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Capricor Therapeutics Inc

Capricor Therapeutics is trending as investors react to a critical legal dispute with Nippon Shinyaku regarding commercial distribution rights ahead of the upcoming August 22 PDUFA date. The community is actively debating whether the company will secure independent commercialization for its DMD therapy, Deramiocel, viewing the lawsuit as a high-stakes hurdle that could significantly impact the stock's valuation upon potential FDA approval.

Intellia Therapeutics, Inc. is a biopharmaceutical company, which engages in the development of curative therapeutics using the CRISPR/Cas9 system. Its CRISPR/Cas9 system transforms medicine by both producing therapeutics that permanently edit and/or correct disease-associated genes in the human body with a single treatment course and creates engineered cells that can treat oncological and immunological diseases. The company was founded by Andrew May, Luciano Marraffini, Rodolphe Barrangou, Nessan Bermingham, Rachel Haurwitz, Erik Sontheimer, Jennifer Doudna and Derrick Rossi in May 2014 and is headquartered in Cambridge, MA.

Intellia Therapeutics Inc

Intellia Therapeutics is currently a focal point for investors as a significant short interest faces potential pressure following strong Phase 3 clinical data for its gene-editing candidate. The community is actively debating the likelihood of a major pharmaceutical buyout and the implications of recent capital raising activities on the stock's future trajectory.

Netflix, Inc. engages in providing entertainment services. It also offers activities for leisure time, entertainment video, video gaming, and other sources of entertainment. It operates through the United States and International geographic segments. The company was founded by Marc Randolph and Wilmot Reed Hastings on August 29, 1997 and is headquartered in Los Gatos, CA.

Netflix Inc.

Netflix Inc

Netflix is facing increased volatility amid market rumors of potential acquisition targets like Lionsgate, which has intensified investor frustration over the stock's recent performance. Community discussion is heavily divided between long-term investors advocating for patience due to strong fundamentals and share buybacks, and skeptics expressing concern over stagnating organic growth and management's shifting M&A strategy.

uniQure NV engages in the discovery, development, and commercialization of innovative gene therapies. Its discoveries intend to treat hemophilia, Huntington's disease, glybera, and cardiovascular problems. The company was founded by Sander J. van Deventer in 1998 and is headquartered in Amsterdam, Netherlands.

uniQure N.V.

uniQure NV

uniQure is seeing massive volatility after the FDA rejected its Phase I/II data for its Huntington's disease gene therapy, mandating a new, randomized, sham-controlled trial instead of the expected accelerated approval path. The community is sharply divided, with frustrated investors debating the ethics of sham surgeries on terminal patients, while many are now bracing for significant delays and potential cash-burn concerns despite the company's existing capital runway.

Sezzle, Inc. engages in the operation of a digital payment platform that enables bank-to-bank transfer of money between consumers and businesses. The company was founded by Charlie G. Youakim, Killian Brackey and Paul V. Paradis on January 4, 2016 and is headquartered in Minneapolis, MN.

Sezzle Inc.

Sezzle is attracting significant attention as investors anticipate a potential short squeeze, fueled by high short interest and anticipation for the upcoming first-quarter earnings report. Community sentiment remains bullish, with many focusing on the company's strong fundamentals and perceived growth potential as a fintech super app, despite broader market volatility and recent board-level governance changes.

Salesforce, Inc. engages in the design and development of cloud-based enterprise software for customer relationship management. Its solutions include sales force automation, customer service and support, marketing automation, digital commerce, community management, collaboration, industry-specific solutions, and salesforce platform. The firm also provides guidance, support, training, and advisory services. The company was founded by Marc Russell Benioff and Parker Harris in 1999 and is headquartered in San Francisco, CA.

Salesforce Inc

Salesforce is trending due to a massive and unexpected sell-off, triggering intense community debate over whether the software sector is facing a long-term structural decline or an oversold buying opportunity. Investors are actively discussing the company's aggressive buyback program, recent acquisitions in the AI agent space, and the broader rotation out of software into speculative AI infrastructure as the primary drivers of this volatility.

CarMax, Inc. is a holding company, which engages in the retail of used vehicles and wholesale of vehicle auction operators. It operates through the CarMax Sales Operations and CarMax Auto Finance (CAF) segments. The CarMax Sales Operations segment consists of all aspects of its auto merchandising and service operations. The CAF segment pertains to its finance operation, which offers vehicle financing services to customers buying retail vehicles. The company was founded by Richard L. Sharp and William Austin Ligon in 1993 and is headquartered in Richmond, VA.

Carmax Inc

CarMax is experiencing significant volatility and downward pressure as shares hit multi-year lows following a leadership change and preliminary quarterly results that fell short of expectations. The community remains deeply divided, with bears pointing to systemic issues like rising subprime delinquencies and weak foot traffic, while bulls argue the stock is severely oversold and represents a deep-value opportunity for long-term patient investors.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Opiant Pharmaceuticals is a pharmaceutical company that develops treatments for drug overdose and addictions leveraging intranasal and injectable delivery technologies. The company, formerly known as Lightlake Therapeutics, was founded in 2009, has a team of addiction experts, and is headquartered in Santa Monica, California.

Opiant Pharmaceuticals Inc

Neutral Sentiment

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

OPNTOpiant Pharmaceuticals Inc

Fundamentals

Feed

News

Sentiment

Fundamentals

Info

Latest OPNT News